Sign up USA
Proactive Investors - Run By Investors For Investors

Dual Therapeutics reports Bristol-Myers Squibb tie-up

Oncology start-up Dual Therapeutics has tied up with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds to treat cancer and other diseases.
Dual Therapeutics reports Bristol-Myers Squibb tie-up
Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialise therapeutics discovered by Dual..

Oncology start-up Dual Therapeutics  has tied up with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds to treat cancer and other diseases.

Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialise therapeutics discovered by Dual.

"We are pleased to collaborate with Bristol-Myers Squibb, a global leader in developing oncology products,"  Baiju R. Shah, chief executive of BioMotiv, the lead investor in Dual Therapeutics.

Dual Therapeutics is based on the work of investigators at Icahn School of Medicine at Mount Sinai and Case Western Reserve University

Bristol-Myers Squibb will pay an undisclosed upfront fee and development costs and Dual Therapeutics will be eligible to receive development and regulatory milestones that could total more than US$255 million for a successful compound approved in multiple indications in addition to royalties on future sales of products discovered in the collaboration.

Giles_55af4ddca6481.jpg


Register here to be notified of future BMY Company articles
View full BMY profile

Bristol Myers Squibb Timeline

Related Articles

picture of pregnant woman
October 10 2016
Stem cell therapies are tipped to be among the next great advances in the treatment of a range of life-threatening ailments and conditions.
Harley Street London street sign
May 27 2016
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
Benjamin Franklin wearing a medical mask
March 24 2016
Constellation has identified a significant market opportunity in healthcare billing management.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC